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Abstract
Background: Since the last review of vaccine safety surveillance data for erythema multiforme 
(EM), Stevens Johnson syndrome (SJS), SJS/TEN, and toxic epidermal necrolysis (TEN) 
(EM/SJS/TEN), over 37 new vaccines have been introduced in the United States. We sought to 
describe reported EM/SJS/TEN after vaccines during 1999–2017.
Methods: We identified U.S. reports of EM/SJS/TEN received by the Vaccine Adverse Event 
Reporting System (VAERS) during 1999–2017. We stratified analysis by condition (EM, SJS, or 
TEN), and analyzed reports by serious or non-serious status, sex, age group, time from vaccination 
to symptom onset, exposure to known causes of EM/SJS/TEN, and vaccines administered. We 
used Empirical Bayesian data mining to detect vaccine-AE pairs reported more frequently than 
expected.
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Results: Of 466,027 reports to VAERS during 1999–2017, we identified 984 reports of EM, 89 
reports of SJS, 6 reports of SJS/TEN, and 7 reports of TEN. Few reports of EM (9%), and most 
reports of SJS (52%), SJS/TEN (100%), and TEN (100%) were serious. Overall, 55% of reports 
described males, 48% described children aged < 4 years; 58% of EM/SJS/TEN occurred ≤ 7 days 
after vaccination. Few reports (≤5%) described exposure to known causes of EM/SJS/TEN. 
Overall, childhood vaccines (e.g., combined measles, mumps, and rubella vaccine) were most 
commonly reported. We identified 6 deaths; 4 were exposed to medications associated with 
EM/SJS/TEN. EM after smallpox vaccine was reported disproportionately among people aged 19–
49 years.
Conclusions: EM/SJS/TEN were rarely reported after vaccination; data mining identified a 
known association between EM and smallpox vaccine.
Keywords
Erythema multiforme; Stevens Johnson syndrome; Toxic epidermal necrolysis; Vaccine; VAERS; 
Vaccine safety; Surveillance; Data mining
1. Introduction
Dermatologic adverse events (AEs) are among the most frequently reported AEs after 
vaccination. The most common dermatologic AEs are redness, swelling, and tenderness at 
the injection site [1], which can occur in up to 90% of persons receiving vaccinations [2]. At 
the other extreme are AEs, such as Henoch-Schönlein purpura after the combined measles, 
mumps, and rubella (MMR) vaccine, for which only isolated case reports exist [3]. While 
some dermatologic AEs can be common to many vaccines (such as tenderness at the 
injection site), other dermatologic AEs can be specific to a particular vaccine, such as 
vesicular lesions after varicella vaccine.
Some dermatologic AEs that have been reported to occur after vaccination involve 
hypersensitivity reactions, such as an allergy to the aluminum in some adjuvanted vaccines 
[4], or lichen planus after hepatitis B vaccine [5]. Erythema multiforme (EM) is a 
hypersensitivity reaction characterized by papules, classically with a ringed, target-like 
appearance often involving the palms of the hands and soles of the feet [1]. More severe 
hypersensitivity reactions include Stevens-Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN), both of which involve blistering and sloughing of skin. [6] SJS and TEN 
also typically involve lesions on mucosal surfaces. SJS and TEN are thought to be related 
conditions of varying severity, depending upon percentage of body surface area involved: 
<10% for SJS, 10–30% for combined SJS/TEN, and >30% of body surface area for TEN 
[7]. Fortunately, EM, SJS, and TEN are rare, occurring with a rate of 4.2 hospitalizations per 
million person-years after exposure to an associated medication [8]; rates after vaccinations, 
as of this writing, are unavailable.
Ball et al previously identified 99 reports of SJS, TEN, and serious reports of EM after 
vaccination received by the Vaccine Adverse Event Reporting System (VAERS) during July 
1990 through September 1999 [9]. Since 1999, over 37 vaccines have been approved for use 
in the United States [10]. Thus, we searched and described reports of EM, SJS, SJS/TEN, 
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and TEN after vaccination (these specific dermatologic AEs will be referred to collectively 
as EM/SJS/TEN) reported to VAERS during 1999–2017, and compared the relative 
frequency of EM/SJS/TEN reported to VAERS by vaccine, to better understand if there are 
any concerning patterns of reported EM/SJS/TEN (e.g., after a specific vaccine, or among a 
particular age group) or other emerging safety concerns.
2. Methods
2.1. Data source
AEs occurring after vaccination can be reported to VAERS, a national spontaneous reporting 
system established in 1990 to monitor AEs that is jointly administered by the Centers for 
Disease Control and Prevention and the U.S. Food and Drug Administration [11,12]. 
VAERS receives reports from healthcare providers, vaccine manufacturers, vaccine 
recipients, and other persons. Reported symptoms and diagnoses are coded using Medical 
Dictionary for Regulatory Activities (MedDRA) Preferred Terms (PTs) [13]. MedDRA PTs 
are not necessarily medically confirmed diagnoses, and multiple MedDRA PTs can be 
assigned to a VAERS report. Federal regulations define a serious report as a report in which 
one or more of the following conditions is reported: death, life-threatening illness, 
hospitalization or prolongation of existing hospitalization, permanent disability, congenital 
anomaly, or birth defect [14]. A report might therefore not be classified as serious, despite 
describing a clinically severe presentation. VAERS personnel routinely request medical 
records for non-manufacturer serious reports. Vaccine manufacturers that directly receive 
reports of AEs typically request and review medical records per regulatory processes [12]; 
these records are not always available to manufacturers. Serious reports from vaccine 
manufacturers therefore often do not contain medical records that VAERS personnel can 
review.
2.2. Descriptive analysis
We searched the VAERS database for U.S. reports of EM/SJS/TEN following vaccination 
received by VAERS during October 1, 1999, through December 31, 2017 (among reports 
received by CDC and FDA through April 27, 2018); reports specifying a vaccination date 
outside the analytic period were excluded. We searched for reports that included the PTs 
“erythema multiforme,” “Stevens Johnson Syndrome,” and “toxic epidermal necrolysis.” We 
also searched text fields for the following terms: “skin ulcer,” “blister,” “blister, infected,” 
and/or “blister, rupture,” where “multiforme,” “John son,” and/or “necrolysis” was also 
present. We combined results from both searches, then deduplicated records.
We reviewed the resulting reports for reports of EM/SJS/TEN that were diagnosed by 
physicians (reported by a physician, or a physician’s diagnosis was documented in available 
medical records). For reports of symptoms consistent with EM/SJS/TEN, but without a 
physician’s diagnosis, we defined (1) EM as papular lesions, classically with a ringed 
(“targetoid”) appearance, usually beginning peripherally and then spreading to the torso, that 
could involve the palms of the hands and/or soles of the feet, without mucosal lesions; (2) 
SJS as peeling or blistering of the skin with lesions on mucosal membranes that involved 
<10% of total body surface area (BSA); (3) SJS/TEN as signs and symptoms consistent with 
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SJS, but involving between 10 and 30% BSA; and (4) TEN as signs and symptoms 
consistent with SJS, involving >30% BSA.
We stratified data by condition (EM, SJS, SJS/TEN, and TEN). For each condition, we 
analyzed reports by sex; age group (<4 years, 4–10 years, 11–18 years, 19–49 years, ≥50 
years, and age not reported), roughly corresponding with the recommended schedules for 
vaccination [15]; seriousness of report (serious or non-serious); and time from vaccination to 
onset of symptoms. Reports were further analyzed for persons with exposure to a known 
trigger [8,10] proximal to onset of symptoms (viral or Mycoplasma infection, medications 
(anticonvulsants, sulfa drugs, penicillins, non-steroidal anti-inflammatory drugs (NSAIDs), 
macrolide antibiotics, and acetaminophen); history of predisposing conditions (past history 
of EM/SJS/TEN, atopic dermatitis, asthma/reactive airway disorder, allergies to medications, 
or malignancy) [16]; and whether vaccines were given alone or concomitantly with other 
vaccines.
2.3. Estimated reporting rates
Estimating reporting rates of AEs after vaccination using data from VAERS is challenging 
because data about doses of vaccine that were distributed or administered are difficult to 
obtain. However, we were able to estimate crude reporting rates of EM, SJS, SJS/ TEN, and 
TEN after varicella vaccine using reports received during 2006 through 2016 as the 
numerator, divided by doses distributed by the manufacturer [17] during the corresponding 
time period (Merck and Company, Inc., personal communication) as the denominator; rates 
were estimated as reports per 1 million doses distributed. For influenza vaccine (all types), 
annual crude reporting rates for EM, SJS, SJS/TEN, and TEN were estimated during 2010 
through 2017 using reports received as the numerator, with population estimates and vaccine 
coverage for that year multiplied as the denominator [18,19]; rates for 2 age groups (1–17 
years, ≥18 years) were estimated. From these annual crude reporting rates, median rates of 
reports per million doses administered were estimated for 2010–2017.
2.4. Data mining (disproportionate reporting)
We used Empirical Bayesian data mining to assess whether vaccine-AE combinations were 
reported more frequently than expected (when compared to all other vaccine-AE 
combinations in the VAERS database) using the Multi-Item Gamma Poisson Shrinker 
(MGPS) algorithm [20]. We analyzed U.S. reports received by VAERS during October 1, 
1999 – December 31, 2017 (received as of April 27, 2018). We stratified by age group (<4, 
4–10, 11–18, 19–49, ≥50 years, and unreported), and adjusted for sex, and year in which the 
report was received by VAERS. We analyzed disproportionate reporting for vaccine-
EM/SJS/TEN combinations using: (1) the PTs “erythema multiforme,” “Stevens Johnson 
Syndrome,” and “toxic epidermal necrolysis”; and (2) PTs included in reports with the 
words “skin ulcer,” “blister,” “blister infected,” or “blister rupture” in the narrative, 
symptoms text, or comments fields, if the words “multiforme”, “Johnson”, and/or 
“necrolysis” were also present. We conducted our analyses for all reports, and serious 
reports only, in Oracle’s Empirica™ Signal System [20,21]. The main statistical scores 
computed were the Empirical Bayes Geometric Mean (EBGM) and its associated 90% 
confidence interval (EB05, EB95). We used the lower 5% bound of the 90% confidence 
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interval for an EBGM (EB05) of ≥2.0 as the threshold to define vaccine-AE combinations 
reported at least twice as often as expected, indicating combinations of potential significance 
[21].
3. Results
3.1. Descriptive analysis
Of 466,027 reports to VAERS during the analytic period [22], we identified 1086 (0.2%) 
reports of EM/SJS/TEN. Overall, over half (51%) of reported EM occurred among children 
aged <4 years (Table 1), with a median age of 3 years (range: <1 year to 89 years); among 
reports of SJS, overall median age was 15 years (range: <1 year to 84 years). Most (91%) 
reports of EM were non-serious, while most (52%) reports of SJS, and all reports of 
SJS/TEN and TEN, were serious. Most reports of EM/SJS/TEN described onset of 
symptoms within 14 days of vaccination; for cases of SJS with known time to onset, 71% 
described onset of symptoms within 3 days of vaccination.
Few reports of EM/SJS/TEN described a known trigger or stimulus for these conditions near 
when vaccine was administered (Table 2). No reports of SJS/TEN or TEN reported recent 
infection (such as with Mycoplasma or herpes simplex virus 1). Of persons with a history of 
EM/SJS/TEN, 4 had a similar reaction to past vaccination: (1) a female aged 15 months with 
EM after varicella vaccine, who later experienced EM after combined measles, mumps, and 
rubella (MMR) vaccine; (2) a female aged 2 years with EM after influenza vaccine, who 
later experienced EM after influenza vaccine; (3) a male aged 10 years with EM after 
combined diphtheria, tetanus, and acellular pertussis (DTaP), who later experienced EM 
after a combined diphtheria tetanus booster; and (4) a male aged 27 years with SJS after 
anthrax vaccine who later experienced SJS after another dose of anthrax vaccine. One 
patient had an active malignancy: a male aged 78 years who was undergoing radiation 
therapy for non-small cell lung cancer, who developed EM 4 days after receiving trivalent 
inactivated influenza vaccine; notably, this patient had been taking phenytoin for 2 months 
prior to developing EM.
The most commonly administered vaccines described in reports of EM/SJS/TEN were 
vaccines commonly administered in infancy and childhood: MMR (22%), DTaP (18%), 
varicella (18%), and 7-valent pneumococcal conjugate (13%) vaccines (Table 3). Among 
reports describing the administration of only one vaccine, the most common vaccines were 
smallpox (16%), trivalent inactivated influenza (15%), and varicella (7%) vaccines.
3.2. Reported deaths
We identified 6 reports of persons who developed EM/SJS/TEN after vaccination, and 
subsequently died (Table 4): 4 received medications known to trigger EM/SJS/TEN prior to 
or at the time of vaccination. Two patients received varicella vaccine, and 2 patients received 
inactivated trivalent influenza vaccine.
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3.3. Estimated reporting rates
During 2006 through 2016, EM after varicella vaccine was reported to VAERS at an 
estimated rate of 1.0 per 1 million doses distributed; SJS after varicella vaccine was reported 
at an estimated rate of 0.1 per 1 million doses distributed. No reports of SJS/TEN or TEN 
after varicella vaccine were identified. Regardless of age group, estimated median reporting 
rates of EM, SJS, and TEN to VAERS during 2010 through 2017 after influenza vaccine (all 
types) were ≤0.1, <0.1, and <0.1 per 1 million doses administered, respectively; no reports 
of SJS/TEN after influenza vaccines were identified.
3.4. Data mining (disproportionate reporting)
We found elevated data mining statistics (EB05 ≥ 2.0) for “erythema multiforme” following 
smallpox vaccination among persons aged 19–49 years. When we restricted data mining 
analyses to serious reports only, or to reports identified through text field searches, we did 
not identify disproportional reporting for any vaccine-EM/SJS/TEN combination.
4. Discussion
Historically, EM/SJS/TEN have rarely been reported after vaccination [1]. Consistent with 
this history, an analysis of VAERS reports during 1990 to 1999 found few reports of SJS 
and/or TEN after vaccination [9]. Our analysis of VAERS data during 1999 through 2017 
identified no new safety concerns, despite the introduction of several new vaccines since 
1999. While these data are reassuring, new vaccines continue to be introduced to the market 
[23,24]. Continued surveillance for increased reporting of EM/SJS/ TEN (SJS and TEN in 
particular) is therefore warranted.
Data from a systematic review by Chahal et al. and case reports from other groups have 
described median ages of 7 years for EM (range of <1–49 years) and 13–15 years (range of 
1–75 years) for both SJS and TEN after vaccination [25,26]. The younger reported median 
age for EM in our analysis might reflect the younger age at which persons receive most of 
their vaccinations [15]. Reported sex was generally consistent with previous analyses [8,27].
Reported times from exposure to the suspected trigger, to onset of the rash, vary for SJS and 
TEN, ranging from a median of 10 days to a median of 3 weeks or longer [28,29]. A median 
of 6 days from vaccination to onset of EM has been observed [25]. Similarly, we observed 
varying reported times to onset of symptoms after vaccination but found that most events 
occurred within 14 days and rarely after 30 days; most SJS with known time to onset began 
within 3 days of vaccination. Notably, AEs are frequently reported when occurring within a 
short time after a potentially attributable trigger, regardless if a true association exists [30].
We observed no concerning patterns of reporting of EM/SJS/TEN after any particular 
vaccine. Reported vaccines seemed to reflect age groups for which vaccines are 
recommended: EM/SJS/TEN were mostly reported after childhood vaccines among persons 
receiving multiple vaccines simultaneously, but mostly reported after smallpox and 
inactivated influenza vaccines among persons receiving single vaccines (Table 3) [15,31]. 
Likewise, our data mining analyses identified no notable vaccine-AE combinations for 
EM/SJS/TEN following vaccination overall. Data mining did identify disproportionate 
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reporting of EM following smallpox vaccination among persons aged 19–49 years. This age 
distribution is consistent with the age ranges of military personnel and selected civilian 
populations vaccinated due to concerns of potential bioterrorism and orthopoxvirus 
outbreaks per U.S. vaccination policy [32–34]. EM is a well-documented complication of 
smallpox vaccination, and the package insert for ACAM2000™ (live vaccinia virus 
smallpox vaccine) includes a “boxed warning” alerting about the risk of “EM major” (i.e., 
SJS), following either primary vaccination or revaccination with live vaccinia virus smallpox 
vaccine. Overall, our observations are consistent with previous descriptions of EM/SJS/TEN 
after vaccination [35–37].
While prior episodes of EM/SJS/TEN in a patient might indicate a predisposition to 
subsequent episodes, the likelihood of such an occurrence is unclear. Of the 4 persons we 
describe who previously experienced EM or SJS after vaccination, two experienced another 
episode of EM or SJS after the same vaccine (positive rechallenge). In a case series of nine 
children with a history of SJS precipitated by Mycoplasma infection, one developed a 
subsequent episode of SJS after a repeat infection with Mycoplasma [38,39]. Likewise, 
persons with a history of EM after infection with herpes simplex virus (HSV) can develop 
subsequent episodes of EM with recurrence of HSV [40]. However, our analysis (Table 2) 
and reports by other investigators [41] describe few persons with exposure to known 
precipitants of EM/SJS/TEN, or a history of allergies or other hyper-sensitivities. Notably, a 
patient who experienced SJS after infection with wild-type influenza B virus received 
multiple seasonal influenza vaccinations with no subsequent episodes of SJS [42]. Together, 
these observations suggest further exploration into predisposing factors for EM/SJS/TEN, 
including vaccines, is warranted.
SJS and TEN can be dire conditions, with case fatalities as high as 35% observed for TEN 
[43]. Consistent with this observation, 5 of the 6 deaths among reports of EM/SJS/TEN after 
vaccination had either TEN or SJS/TEN (Table 4). However, any association with 
vaccination is dubious, given that 4 reports described receipt of a medication known to cause 
SJS or TEN. Additionally, 1 report involved treatment for anti-N-methyl-D-aspartate 
(NDMA) receptor encephalitis and subsequent TEN; while treatment was unspecified, 
cyclophosphamide has been used to treat anti-NDMA receptor encephalitis and is known to 
cause SJS and TEN [44,45]. The 1 report of death after EM described a woman who 
experienced considerable vomiting, subsequent dehydration, and shock; the degree to which 
EM contributed to her death is uncertain.
Previous investigators have estimated rates of EM/SJS/TEN after drug exposure as high as 
200 per 1 million persons exposed (phenobarbital) [8]. Our estimated reporting rates of 
EM/SJS/TEN after varicella and influenza vaccines were well below this figure (i.e., the 
highest estimate was 1.0 report of EM per million doses of varicella vaccine distributed), a 
notable observation considering that varicella vaccine was one of the most commonly 
reported vaccines after which EM/SJS/TEN occurred. Despite potentially underestimating 
rates, our data suggest that EM/SJS/TEN is reported no more frequently after vaccination 
than after known causes of these conditions. Importantly, while EM/SJS/TEN can occur 
after vaccination, previous post-marketing analyses and case-control studies demonstrate 
that vaccination itself does not increase the likelihood of these conditions [46,47].
Su et al. Page 7
Vaccine. Author manuscript; available in PMC 2021 February 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
These data have limitations. As a passive reporting system, VAERS is subject to reporting 
biases, under-reporting, inconsistent data quality and completeness, and changes in reporting 
over time; reports to VAERS also lack an unvaccinated comparison group. These limitations 
generally do not allow VAERS data to determine if a vaccine caused a particular adverse 
event, including EM/SJS/TEN [11]. Because data on doses distributed or administered are 
not available for many of the vaccines in this analysis, our ability to estimate reporting rates 
for EM/SJS/TEN was limited to varicella and influenza vaccines and are likely 
underestimates. Despite these limitations, results from data mining reflect known 
associations (i.e., smallpox vaccine and EM) [48,49].
While EM (and to a lesser degree, SJS) is typically benign and self-limiting [1,50], SJS/TEN 
and TEN can be life-threatening. [43] Surveillance for unexpected, increased reporting of 
these conditions after vaccination should therefore continue. Fortunately, our observations 
and the observations of other investigators [1,9] suggest that EM/SJS/TEN rarely occur after 
vaccination.
Abbreviations:
AE adverse event
BSA body surface area
CDC Centers for Disease Control and Prevention
DTaP combined diphtheria, tetanus, and acellular pertussis vaccine
EM erythema multiforme
FDA Food and Drug Administration
IIV trivalent inactivated influenza vaccine
MGPS Multi-Item Gamma Poisson Shrinker
MedDRA Medical Dictionary for Regulatory Activities
MMR combined measles, mumps and rubella vaccine
NDMA N-methyl-D-aspartate
NSAID non-steroidal anti-inflammatory drug
PNC7 7-valent conjugated pneumococcal vaccine
PT Preferred Term
SJS Stevens Johnson Syndrome
TEN toxic epidermal necrolysis
VAERS Vaccine Adverse Event Reporting System
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